miR-186过表达慢病毒载体的构建及鉴定

doi:10.13481/j.1671-587x.20190504

摘要/Abstract

摘要： 目的：构建miR-186过表达慢病毒载体并包装慢病毒，探讨miR-186在人胚胎肾细胞（HEK）293T细胞系中的感染效率和表达水平。方法：以Hsa-miR-186前体序列为模板，设计并合成引物，PCR法扩增pre-miR-186基因序列，并将其克隆到携带EGFP/Puromycin的慢病毒载体FV040中，经EcoRⅠ和AgeⅠ酶切及测序鉴定后获得重组慢病毒载体。利用Lipofectamine 2000将重组慢病毒质粒FV040 Vector和FV040 miR-186分别与辅助质粒通过共转染至HEK293T细胞中，48 h后收集慢病毒，以FV040 Vector慢病毒作为对照组，FV040 miR-186作为实验组，分别感染HEK293T细胞。感染48 h后，观察HEK293T细胞中绿色荧光的分布情况，并采用实时荧光定量PCR法检测miR-186的表达水平。结果：测序分析，miR-186过表达慢病毒与GenBank上公布的miR-186序列完全一致。与对照组（0.8387±0.1456）比较，实验组HEK 293T细胞中miR-186表达水平（12.6400±0.7884）明显升高（t=14.72，P<0.01），约为对照组的15.07倍。结论：成功构建miR-186过表达慢病毒载体并包装出慢病毒，miR-186慢病毒成功感染HEK293T细胞，miR-186表达水平在HEK293T细胞中明显升高。

关键词: miR-186, 慢病毒, HEK293T细胞, 过表达慢病毒载体, 绿色荧光蛋白

Abstract: Objective:To construct the miR-186 overexpression lentiviral vector and package the lentivirus, and toexplore the infection efficiency and the expression level of miR-186 in the HEK293T cells. Methods:The Hsa-miR-186 precursor sequence was used as a template to design and synthesize the primer, and the the pre-miR-186 gene was amplified by PCR. The pre-miR-186 gene sequence was cloned into the lentiviral vector FV040 carrying EGFP/Puromycin cassette. The recombinant lentiviral vector was digested by EcoRⅠand AgeⅠrestriction endonuclease and confirmed by sequencing. The recombinant FV040 Vector and FV040 miR-186 were co-transfected into the HEK293T cells with the helper plasmids using Lipofectamine 2000, respectively; the FV040 Vector lentivirus (control group) and the FV040 miR-186 lentivirus (experiment group) were collected and used to infect the HEK293T cells 48 h after transfection, respectively. The green fluorescence distribution in the HEK 293T cells was observed 48 h after transfection, and the expression level of miR-186 was determined by real-time fluorescence quantitative PCR. Results:The sequencing analysis results indicated that the sequence of miR-186 overexpressing lentivirus was identical with the sequence of miR-186 published on GenBank. The titers in control group and experiment group were 6×10⁸ TU·mL^-1 and 5×10⁸ TU·mL^-1, respectively. The relative expression level of miR-186 in the HEK293T cells in experiment group (12.640 0±0.788 4) was significantly increased by 15.07 times (t=14.72,P<0.01) compared with control group (0.838 7±0.145 6). Conclusion:The lentiviral vector which overexpresses miR-186 is constructed successfully and the miR-186 lentivirus is prepared. The HEK 293T cells are infected with miR-186 lentivirus suceessfully and the expression level of miR-186 in the HEK 293T cells is increased significantly.

Key words: miR-186, lentivirus, HEK293T cells, overexpression lentiviral vector, green fluorescence protein

中图分类号:

R346

李胜男, 王梦旭, 胡伟东, 陈少凤, 陈杏兰, 李友. miR-186过表达慢病毒载体的构建及鉴定[J]. 吉林大学学报(医学版), 2019, 45(05): 997-1002.

LI Shengnan, WANG Mengxu, HU Weidong, CHEN Shaofeng, CHEN Xinglan, LI You. Construction and identification of miR-186 overexpression lentiviral vector[J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 997-1002.

参考文献

[1] AMBROS V. The functions of animal microRNAs[J]. Nature, 2004,431(7006):350-355.
[2] DOENCH J G, SHARP P A. Specificity of microRNA target selection in translational repression[J]. Genes Dev, 2004,18(5):504-511.
[3] HOSIN A A, PRASAD A, VⅡRI L E,et al. MicroRNAs in atherosclerosis[J]. J Vasc Res, 2015, 51(5):338-349.
[4] SAVITT J M, DAWSON V L, DAWSON T M. Diagnosis and treatment of Parkinson disease:molecules to medicine[J]. J Clin Invest, 2006, 116(7):1744-1754.
[5] LEE Y, AHN C, HAN J J, et al. The nuclear RNase Ⅲ Drosha initiates microRNA processing[J]. Nature, 2003,425(6956):415-419.
[6] XIE Y M, CHEN Y H. microRNAs:Emerging targets regulating oxidative stress in the models of Parkinson's disease[J]. Front Neurosci, 2016,10:298.
[7] WANG K J, ZHAO X, LIU Y Z, et al. Circulating MiR-19b-3p, MiR-134-5p and MiR-186-5p are promising novel biomarkers for early diagnosis of acute myocardial infarction[J]. Cell Physiol Biochem, 2016, 38(3):1015-1029.
[8] ZHAO X, WANG Y L, DENG R, et al. miR186 suppresses prostate cancer progression by targeting Twist1[J]. Oncotarget, 2016. 7(22):33136-33151.
[9] CAI J C, WU J H, ZHANG H Z, et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation[J]. Cancer Res, 2013, 73(2):756-766.
[10] HU X D, LIU Y F, AI P, et al. MicroRNA-186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1[J]. Exp Ther Med, 2019, 17(3):1930-1938.
[11] WU J, SONG J X, WANG C, et al. Identification of serum microRNAs for cardiovascular risk stratification in dyslipidemia subjects[J]. Int J Cardiol, 2014,172(1):232-234.
[12] WANG R, BAO H, ZHANG S, et al. miR-186-5p promotes apoptosis by targeting IGF-1 in SH-SY5Y OGD/R Model[J]. Int J Biol Sci, 2018, 14(13):1791-1799.
[13] WU D M, WEN X, WANG Y J, et al. Effect of microRNA-186 on oxidative stress injury of neuron by targeting interleukin 2 through the janus kinase-signal transducer and activator of transcription pathway in a rat model of Alzheimer's disease[J]. J Cell Physiol, 2018, 233(12):9488-9502.
[14] KIM J, YOON H, CHUNG D E, et al. miR-186 is decreased in aged brain and suppresses BACE1 expression[J]. J Neurochem, 2016, 137(3):436-445.
[15] DELAY C, DORVAL V, FOK A, et al. MicroRNAs targeting Nicastrin regulate Abeta production and are affected by target site polymorphisms[J]. Front Mol Neurosci, 2014, 7:67.
[16] GIRI M, SHAH A, UPRETI B, et al. Unraveling the genes implicated in Alzheimer's disease[J]. Biomed Rep, 2017, 7(2):105-114.
[17] HØGH P. Alzheimer's disease[J]. Ugeskr Laeg, 2017, 179(12):V09160686.
[18] HAMANO T, HAYASHI K, SHIRAFUJI N, et al. The implications of autophagy in Alzheimer's disease[J]. Curr Alzheimer Res, 2018,15(14):1283-1296.
[19] BERTRAM L, LILL C M, TANZI R E. The genetics of Alzheimer disease:back to the future[J]. Neuron, 2010,68(2):270-281.
[20] KIM J, BASAK J M, HOLTMAN D M. The role of apolipoprotein E in Alzheimer's disease[J]. Neuron, 2009,63(3):287-303.
[21] LUKIW W J, ANDREEVA T V, GIGORENKO A P, et al. Studying micro RNA function and dysfunction in Alzheimer's disease[J]. Front Genet, 2012, 3:327.
[22] QIAN Q, ZHANG J,HE F D, et al. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease[J]. FASEB J, 2019, 33(3):4404-4417.
[23] Boscher E, Husson T, Quenez O, et al. Copy number variants in miR-138 as a potential risk factor for early-onset Alzheimer's disease[J]. J Alzheimers Dis, 2019,68(3):1243-1255.
[24] DELAY C, CALON F, MATHEWS P, et al. Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function[J]. Mol Neurodegener, 2011,6:70.
[25] LU Y, TAN L, WANG X. Circular HDAC9/microRNA-138/Sirtuin-1 pathway mediates synaptic and amyloid precursor protein processing deficits in Alzheimer's disease[J]. Neurosci Bull, 2019,18:1-12.
[26] 赵静,杨兴武,李京涛,等.基于高通量测序的肝癌circRNA-miRNA-mRNA调控网络构建及功能富集分析[J].临床肝胆病杂志,2019,35(8):1740-1744.
[27] 李琦,邹志余,杨瑞泽,等.慢病毒载体介导增强型绿色荧光蛋白筛选稳定转染的兔骨髓间充质干细胞[J].西安交通大学学报:医学版,2019,40(4):619-623.
[28] NASRI M, KARIMI A, ALLAHBAKHSHIAN FARSANI M. Production, purification and titration of a lentivirus-based vector for gene delivery purposes[J]. Cytotechnology, 2014,66(6):1031-1038.